Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Christopher Hanson
Christopher Hanson
Associate
Washington +1 202 662 5977 chanson@cov.com Download V-card

Christopher Hanson advises international and domestic clients on regulatory strategies and compliance for medical devices, pharmaceuticals, biological products, cosmetics, animal products, radiation-emitting electronic products, and laboratories. His broad range of clients include large multinational companies, venture capital firms, industry associations, clinical and forensic laboratories, and development-stage companies.

Mr. Hanson has extensive experience counseling clients on interactions with state, federal, and foreign regulatory agencies, including the Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA), the Federal Trade Commission (FTC), and the Centers for Medicare and Medicaid Services (CMS).

  • Co-draft legislation successfully signed into law in California and New Jersey concerning the regulation of state clinical laboratories.
  • Prepare FDA public comments and Congressional strategy on behalf of an industry association regarding medical device and radiation-emitting electronic product proposed rulemakings.
  • Draft Congressional white paper and request for a hearing in response to FDA’s Notice of Opportunity for Hearing (NOOH), proposing to withdraw approval of certain new animal drug applications (NADAs).
  • Represent industry association in submitting public comments to Congress concerning in vitro diagnostic (IVD) draft legislation.
  • Advise industry association regarding FDA regulatory aspects of 21st Century Cures Act and the Food and Drug Administration Reauthorization Act of 2017.
  • Write position papers concerning proposed legislation involving pharmaceutical and medical device regulation in foreign jurisdictions, including Canada and India.
  • Advised global healthcare company GSK on FDA and CLIA regulatory components of the company's $300 million equity investment and collaboration with genetic testing and data science company 23andMe -- a collaboration focused on R&D of new medicines, using human genetics as the basis for discovery.
  • Prepare industry association public comments concerning the content of risk information in the major statement in DTC prescription drug broadcast advertisements.
  • Conduct large-scale, internal assessment of multinational pharmaceutical company’s manufacturing division.
  • Draft response to an FDA “It Has Come to Our Attention” (IHCTOA) letter concerning a diagnostic product and prepare FDA Pre-Submission (Pre-Sub) materials.    
  • Provide FDA regulatory diligence to client for $575 million acquisition of a branded respiratory portfolio.
  • Provide FDA regulatory diligence to client for $1.7 billion acquisition of a clinical-stage biopharmaceutical company.
  • Advise underwriters in $175 million follow-on public offering of common stock by molecular diagnostics company.
  • Represent top global pharmaceutical company in internal review of procedures and policies concerning investigator-initiated trials (IITs).
  • Represent client in internal review of procedures and policies concerning cosmetic product labeling.

Pro Bono

  • Represent Federally Qualified Health Center (FQHC) in preparing FDA public comments concerning agency blood donation guidelines.    
  • Represent LGBT organization in litigation involving transgender military service members.
  • Successfully represent Latin American immigrant in U visa application.
  • Represent LGBT organization in preparation for potential election referendum on state transgender rights law.
  • Advise transgender individuals on legal name and gender change procedures in Maryland, Virginia, and Washington, DC.
  • Represent federal inmate in seeking a Presidential clemency grant.
  • Conduct survey of state Medicaid and prescriptive authority law for health care non-profit.

Memberships and Affiliations

  • Harvard University, Divinity School Alumni/ae Council (Chairperson, 2016-2017) and Divinity School Bicentennial Host Committee (Co-Chair)
  • Yale College, Class of 2005 Reunion Chair and Association of Yale Alumni (AYA) Class Representative
  • Point Foundation, Wells Fargo Scholar and Mentorship Committee (former)

Previous Experience

  • United States Senate, Constituent Services (2008-2010)
  • Harvard University, Harvard Humanitarian Initiative Instructor (2008)
  • Yale University, Assistant Director of Undergraduate Admissions (2005-2007)